BioSpace News Archive

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new and real-world research demonstrating the value of ProFound AI® for Digital Breast Tomosynthesis (DBT) will be highlighted at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).

Athenex, Inc., (NASDAQ: ATNX), announced today that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for review .

OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 through December 2, 2021.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the 2nd Annual H.C. Wainwright Psychedelics Conference.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.

Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal second-quarter results for the three-month period ending September 30, 2021.

Shanghai Junshi Biosciences Co., Ltd. announced that the National Medical Products Administration of China has approved its supplemental New Drug Application for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma.

Funding will Advance Immusoft’s Immune System Programming Platform.

Marathon Asset Management Announces Acquisition of Kaléo.

Celsion Corporation (NASDAQ: CLSN), announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a presentation on the Company’s GEN-1 interleukin 12 (IL-12) immunotherapy program at the Cytokine-Based Cancer Immunotherapies Summit being held in Boston on November 30 to December 2, 2021.